Counterintuitive Cure: A Nanovaccine That Stops Autoimmune Disease by Boosting the Immune System

A new treatment prevents type 1 diabetes in mice by turning the immune system on itself















Share on Tumblr



TRICKING T CELLS: The nanovaccine fights type 1 diabetes by boosting the immune system's built-in safety mechanism--regulatory T cells that squelch overactive immune responses. Image: ISTOCKPHOTO/Eraxion

The human body's immune system can quickly track down and kill cells that don't belong. Take certain kinds of bacteria: molecules on their surfaces flag them as foreign invaders, alerting the body's defenders to the breach and drawing a full-fledged attack on anything waving that molecular flag. But sometimes the system mistakenly attacks the body's own cells. The result is autoimmune disease, such as type 1 diabetes, in which the insulin-producing beta cells of the pancreas are attacked and destroyed by T cells.

Scientists have struggled to find ways to treat autoimmune disease without compromising overall immunity. Therapies that suppress the immune system carry the risk of letting infections and even tumors go unchecked. But researchers in Canada have found a way to prevent type 1 diabetes in mice by doing just the opposite—vaccinating to boost the immune system.

The approach, published April 8 in Immunity, exploits the immune system's built-in safety mechanism—a group of regulatory T cells whose job is to squelch overactive immune responses.

"Essentially, there is an internal tug-of-war between aggressive T cells that want to cause [an autoimmune response] and weaker T cells that want to stop it from occurring," says study senior author Pere Santamaria from the Julia McFarlane Diabetes Research Center at the University of Calgary in Alberta. Although they have seemingly opposite effects, these different classes of T cells are "musicians in the same orchestra," Santamaria explains. And they take directions from the same conductor—the antigen-presenting cell (APC).

APCs are specialized white blood cells that grab tiny bits of protein off the surfaces of other cells (like invaders or, in the case of diabetes, beta cells), chop them into pieces (antigens) and present them to T cells to instigate the immune response. "T cells have to be fed," Santamaria says. "If there is no antigen-presenting cell, there is no immune response."

When the aggressive, autoimmune disease-causing T cells are presented with antigens from dying beta cells, they keep attacking and killing the beta cells. But when the weak T cells that want to stop the disease are presented with those same antigens, they kill the APC. "A single weak T cell can blunt the problem by killing the orchestra leader," Santamaria says. And unlike aggressive T cells that die shortly after killing their targets, weak T cells proliferate. "They become long-living cells that attempt to regulate the disease," Santamaria says.

Santamaria designed a "vaccine" to boost the activity of the weak T cells. He used nanoparticles—spheres thousands of times smaller than a single cell—that were coated with beta cell antigens. In doing so, he created an APC doppelganger that could repeatedly activate the weak T cells, causing them to proliferate and kill the real APCs. The nanoparticles shield the antigens from degradation, meaning they stay in the system much longer, so they can be delivered at fewer intervals and at lower doses.

The nanovaccine prevented diabetes in a prediabetic mouse model and restored normal blood sugar levels in diabetic mice. Santamaria hopes to translate his exciting finding into human clinical trials. "We know what we want the compound to look like for use in humans—it's not a pie in the sky," he says. "But launching a clinical trial is not a trivial task. It requires that we do our homework properly."

Over 23 million people in the U.S. have diabetes, according to the most recent report jointly produced by the U.S. Centers for Disease Control, the National Institutes of Health (NIH) and the American Diabetes Association, although only 5 to 10 percent of those cases are thought to be autoimmune (type 1 diabetes). Type 1 diabetics have to carefully monitor their blood glucose levels and routinely administer insulin to keep them down. They have a heightened risk for kidney failure, heart and eye problems, and nerve disease.

Autoimmune disease affects up to 23.5 million Americans, according to the NIH, and it is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years. Santamaria plans to test his approach in models of other autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. "We're trying to extend this paradigm to see if it applies to other autoimmune disorders, as well. We think it will but that remains to be seen. That’s our hope and dream."



14 Comments

Add Comment
View
  1. 1. jm111 07:04 PM 4/8/10

    Innovative ! We need new approaches....I hope this treatment gets the clinical trial.

    My congrats to the researchers...Keep goiing you will get there !

    Reply | Report Abuse | Link to this
  2. 2. quincykim 09:23 PM 4/8/10

    Excellent news, I hope the trials go well.

    Reply | Report Abuse | Link to this
  3. 3. 2manyRareDiseases 12:57 AM 4/9/10

    Wonderful, yet another glimmer of hope at the end of a very dark tunnel! Keep me informed about clinical trials as my primary auto-immune disease is Behcet's Disease, a vasculitis which is "related to" RA, MS and Lupus. I believe that scientists world-wide should share medical knowledge and discoveries and not keep things quiet for potential $$$. Patients need treatments now and more and more patients will discover that they too have some "incurable" disease that requires a complete change of life so to say. Good luck and work hard please and thank you for your amazing discovery!

    Reply | Report Abuse | Link to this
  4. 4. Nazreel 05:14 AM 4/9/10

    Excellent! I have Mixed Connective Tissue Disorder and Pulmonary Arterial Hypertension. It would be lovely to have some hope like this rather than just playing a holding game and hoping I don't get any worse.

    Others have worse diseases than I do too. Autoimmune diseases are often neglected. This would be a real ray of hope.

    Reply | Report Abuse | Link to this
  5. 5. Wayne Williamson 02:17 PM 4/10/10

    great news...now get it out of the lab....
    i think this could be applicable to many other things including cancer...

    Reply | Report Abuse | Link to this
  6. 6. Adara 11:29 PM 4/10/10

    Thank you for your research. You are giving hope to so many people that deal with autoimmunity. I hope that the next organs that are researched are thyroid and adrenal glands.
    Thank you again,
    Adara

    Reply | Report Abuse | Link to this
  7. 7. irishcocacola 01:23 AM 4/11/10

    A bit premature, but sounds like a potential cure? Cool!

    Reply | Report Abuse | Link to this
  8. 8. chenhongyi 12:51 AM 4/12/10

    That is a hope and dream.Thank you for your research

    Reply | Report Abuse | Link to this
  9. 9. Mark Pine 01:58 PM 4/15/10

    I wish the reported had explained why the nanovaccine stimulates the T-reg cells but not T-eff cells.

    Reply | Report Abuse | Link to this
  10. 10. Mark Pine 01:59 PM 4/15/10

    I wish the reported had explained why the nanovaccine stimulates the T-reg cells but not the T-eff cells.

    Reply | Report Abuse | Link to this
  11. 11. bucketofsquid 04:48 PM 4/15/10

    Excellent news but I've read many similar articles over the last decade and none of these other miracles has hit the market.

    I guess we just wait and see.

    Reply | Report Abuse | Link to this
  12. 12. Rea 12:07 PM 4/20/10

    I'm still trying to understand how autoimmunity works. I have Birdshot Chorioretinopathy a supposedly rare form of blinding posterior uveitis - however, having set up a patient group and undertaken prelim research, we are seeing an exponential rise in cases of Birdshot. All of us are on txic regimes of two immunosuppressants and high doses of steroids. if this works, we will be so pleased. anyone with Birdshot can contact us at world wide web birdshot dot org dot uk

    Reply | Report Abuse | Link to this
  13. 13. JoanK 06:31 PM 4/23/10

    A very similar approach is being developed by a New Zealand firm called Innate Therapeutics, which is tackling progressive MS as a first indication. They hope to begin Phase 2 trials this year with their microparticle immune stimulant, which in compassionate use studies in MS patients in NZ has shown activity.

    Reply | Report Abuse | Link to this
  14. 14. benwon 10:08 PM 5/26/11

    Thank you! . I hope that the next organs that are researched are thyroid and adrenal glands.

    Regards
    Joshua from <a href="http://www.convertmovtoavi.net">mov to avi converter</a>

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital

Latest from SA Blog Network

  SA Digital

Science Jobs of the Week

Email this Article

Counterintuitive Cure: A Nanovaccine That Stops Autoimmune Disease by Boosting the Immune System

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X